In lung cancer, targetable activating alterations in cancer genes, such as EGFR, ALK, RET, ROS1 and MET, are usually mutually exclusive. Rare lung cancer cases with coexistent alterations of EGFR and ALK or EGFR mutations with RET or ROS1 rearrangements have been reported. In this study, we report 15 patients (3 men and 12 women; 14 Caucasians and 1 African American) with ages ranging from 43 to 81 years (median 60 years) with lung adenocarcinoma in which coexistent alterations of two cancer-associated genes, including ALK, ROS1, or RET rearrangement or MET amplification were present. The combination of alterations detected by fluorescence in situ hybridization included ALK combined with ROS1 (n = 4), ALK with MET (n = 3), ALK with RET (n = 1); RET with MET (n = 4), RET with ROS1 (n = 2), and ROS1 combined with MET (n = 1). The frequencies of involvement were similar for all 4 genes, 53% for both ALK and MET (n = 8), 47% for both RET and ROS1 (n = 7). Activating gene mutations were also detected by next-generation sequencing for TP53 (n = 6), EGFR (n = 5), KRAS (n = 3) and STK11 (n = 2). Nine patients reported a smoking history (8 heavy and 1 light) and 6 patients were non-smokers. These findings suggest the need for assessing a panel of genes in lung cancer. Since targetable agents are available for each of these activating alterations, treatment with more than one targeted agent may be beneficial for this rare group of patients.
Lung cancer is the most common cause of cancerrelated deaths in the United States and many other countries. 1, 2 The development of tyrosine kinase inhibitors against epidermal growth factor receptor (EGFR) gene mutations (eg, erlotinib) and anaplastic large-cell lymphoma kinase (ALK) gene rearrangement (eg, crizotinib) has dramatically improved the outcome of patients with lung cancer. [3] [4] [5] [6] Additional novel oncogenic fusion genes with tyrosine kinase functions, such as RET and ROS1 as well as fusions genes combined with MET amplification have been identified and tyrosine kinase inhibitors targeting these molecular aberrations, eg, vandetanib against RET rearrangement, 7-9 have entered into clinical trials. Historically, activating cancer gene mutations have been considered as mutually exclusive in lung cancer. 10 However, a group of patients bearing coalterations of EGFR and ALK has been reported recently, [11] [12] [13] [14] and further studies have demonstrated that the addition of ALK inhibitor therapy improved the overall survival of these patients. 15 Co-alterations of EGFR with genes other than ALK (eg, ROS1) have been reported in a few cases, [16] [17] [18] but co-alterations of ALK, RET, ROS1 or MET in lung cancer have not been reported to the best of our knowledge. In this study, we report 15 cases of lung adenocarcinoma in which abnormalities of two cancer-associated genes including ALK, RET, ROS1 or MET. In 5 of these cases activating EGFR mutations were also present.
Materials and methods

Patients
We searched the database of the Clinical Cytogenetics Laboratory at The University of Texas MD Anderson Cancer Center for cases of lung cancer assessed by fluorescence in situ hybridization (FISH) for abnormalities of ALK, RET, ROS1 or MET. Fifteen cases with positive results of more than one of these genes were identified and a thorough chart review was performed. The clinical and laboratory information were collected and reviewed by following institutional guidelines with informed consent in accord with the Declaration of Helsinki.
Fluorescence In Situ Hybridization and Scoring
All tissue FISH tests were performed using formalin fixed, paraffin-embedded tissue sections of primary and/or metastatic lung cancer specimen and were validated for these specimens following the American College of Medical Genetics and Genomics guidelines. 7, 19 The FDA-approved, LSI ALK dual color, breakapart probe was applied for detection of ALK rearrangement (Abbott Molecular, Des Plaines, IL). This probe hybridizes to band 2p23 (spectrum green on the centromeric side and spectrum orange on the telomeric side of the ALK breakpoint). Fifty nuclei were analyzed routinely, but the analysis was extended to 100 nuclei if results from counting 50 nuclei were indeterminate. The following cutoffs have been established in our laboratory: positive signal pattern in 425 cells of 50-nuclei analysis or in 415% of 100-nuclei analysis (Figure 1a) .
The Clear-View FISH RET dual color, breakapart probe from CymoGen DX was applied to detect RET rearrangement (Biocare Medical, Concord, CA). The probe hybridizes to band 10q11.21 (red on the centromeric side and green on the telomeric side of the RET breakpoint). Two hundred interphase nuclei were studied for each case. The cutoff values for a positive RET rearrangement established at 95% (P o 0.05) confidence level are: 47.9% for one red, one green, one fusion (1R1G1F) signal pattern (positive for RET rearrangement) and 43.1% for The XT ROS1 dual color, breakapart probe was used to detect ROS1 rearrangement detection (MetaSystems Group, Newton, MA). This probe hybridizes to 6q22 (red on the centromeric side and green on the telomeric side of the ROS1 breakpoint). Two hundred interphase nuclei were studied for each case.
The cutoff values for a positive ROS1 rearrangement established at 95% (P o 0.05) confidence level are: 43.5% for either one but not a combination of the following three signal patterns: one red, one green, one fusion (1R1G1F) signal pattern (positive for ROS1 rearrangement) and one red, one fusion (1R1F) signal pattern (positive for ROS1 rearrangement with 5′ deletion). A cutoff value of 43.5% was established for one green, one fusion (1G1F) signal pattern indicating a positive result for 3' deletion with unknown clinical significance ( Figure 1c ).
The CymoGen DX MET/CC7 DNA Probe Kit was used for detection of MET amplification (Biocare Medical). The MET probe (red color) is specific for the MET locus (7q31) and CC7 probe (green color) is specific for the alpha satellite DNA sequences at the centromeric region of chromosome 7 (7p11.1-q11.1). Sixty interphase cells were studied for each case. These criteria are used for a positive MET amplification: 1). MET:CC7 ratio ≥ 2.0; 2). MET:CC7 ratio o 2.0, but average MET signal counts in each cell ≥ 5; 3). Over 10% of the tumor cells showed ≥ 20 copies of MET signals or signal clusters ( Figure 1d ). This is to point out that signal patterns of 1R1G ≥ 2 F were frequently observed in our tissue FISH tests for ALK, RET and ROS1 rearrangement (eg, Figures 1a and c). They were considered as positive results with additional gain/amplification of an intact gene, although the clinical significance of gain/amplification of intact ALK, RET or ROS1 gene generally remains unknown.
Next-Generation DNA Sequencing for Detection of Gene Mutations
DNA was isolated from tumor tissues and targeted next-generation DNA sequencing was performed using the Ion Torrent PGM with the Ion AmpliSeq Cancer Hotspot Panel as described previously. 20 Most of the cases included in this study were tested with a 50-gene hotspot panel, while the other cases were recently tested with an expanded 128-gene hotspot panel.
Results and discussion
Our laboratory has provided tissue FISH tests for ALK, RET, ROS1 rearrangement or MET amplification for patients with primary or metastatic lung cancer since February, 2010. At the end of 2016, a total of 5206 cases have been tested, of which 1251 (24%) were tested for all 4 markers, 609 (12%) for 3 markers, 768 (15%) for two markers and 2578 (50%) for one marker, respectively. The rates of a positive result are: 7% (238/3382) for ALK, 2% (32/1782) for ROS1, 1% (33/2379) for RET, and 5% (177/3398) for MET respectively, which are very similar to the prevalence of these abnormalities reported from a study of 1139 Chinese lung cancer patients 21 as well as other patient populations. 22 Among these positive cases, 15 (Table 1) cases were identified with concurrent rearrangement of two cancer-associated genes including ALK, RET and ROS1 and/or with MET amplification. Fourteen of these cases that were tested for all 4 genes whereas case 5 was tested for 3 markers (not RET). Therefore, the estimated dual positivity rate is 0.6% (15/2628) if cases with two or more tested markers are included or up to 1.1% (14/1251) if the cases with 4 tested markers are included in our study.
To the best of our knowledge, this is the first report showing concurrent rearrangement or amplification of ALK, RET, ROS1 or MET in lung cancer cases. As shown in Table 1 , the combination of alterations exists in various forms, eg, ALK rearrangement combined with ROS1 (n = 4, cases 5-8) or RET rearrangement (n = 1, case 4); RET rearrangement combined with ROS1 rearrangement (n = 2, cases 13 and 14); as well as MET amplification combined with ALK (n = 3, cases 1-3), RET (n = 4, cases 9-12) or ROS1 rearrangement (n = 1, case 15). The frequency of involvement is similar for all 4 biomarkers: 53% (8/15) for both ALK and MET and 47% (7/15) for both RET and ROS1 (n = 7). Interestingly, two cases (cases 9 and 10) exhibited unusual RET FISH signal patterns that have not been reported previously. In case 9, a signal pattern of 0R3~20G1~3F was detected indicating a simultaneous deletion of 5'RET and duplication/amplification of 3'RET. Lee et al 23 has reported a RET rearrangement positive case with a predominant signal pattern of 1R2G1F indicating a gain of an extra copy of 3'RET, but no amplification of 3'RET. In case 10, the predominant signal pattern is 1R1G3~6F, indicating RET rearrangement with gain of multiple extra copies of an intact RET gene. The clinical significance of a RET amplification in lung cancer remains unknown, but a previous study correlated this finding with coexistence of EGFR mutations. 24 In the past, mutations involving genes with tyrosine kinase function, such as EGFR, KRAS, HER2, BRAF, ALK, RET, ROS1 and MET were viewed as independent, mutually exclusive events. 10 However, in recent years cases of lung cancer with coexistent alterations of EGFR and ALK or other genes have been reported by others. For example, over 20 cases of lung cancer with simultaneous alterations of EGFR and ALK or EGFR and ROS1 have been reported. [16] [17] [18] Jurmeister et al has reported 3 ALK rearranged lung cancer cases that also harbored MET protein 25 Several research groups have reported that lung cancer patients with alterations of both EGFR and ALK have distinctive clinical characteristics and they have suggested that adding an ALK inhibitor to therapy can improve overall survival. 11, [14] [15] [16] All these data therefore show the coexistence of two (or more) driver mutations in lung cancer cases and that these combinations have potential clinical implications in affected patients. 3, 5, 16 The low frequency of coexistent driver mutations of two (or more) genes including ALK, RET, ROS1 and MET is likely attributable to two reasons: 1) A low incidence of ALK, RET, ROS1 rearrangement as well as MET amplification in lung cancer; 21, 22 2) A change in clinical practice for patients with lung cancer has led to more rigorous testing for these genetic abnormalities. In support to the second reason, less than 25% of all lung cancer cases had been tested for all 4 markers simultaneously during the past 6 years at our center.
The demographic data for the 15 patients in this study shows a female predominance (12 women and 3 men) with a median age of 60 years (range, 43 to 81 years). Fourteen patients are Caucasians and one is an African American. Nine patients reported a smoking history (8 heavy and 1 light) and 6 patients were non-smokers. The pathological diagnosis of lung adenocarcinoma was established in these patients from 3 to 79 months (median 20 months) before FISH testing was performed. Three patients had an early-stage lung adenocarcinoma (stage I: case 6; stage II: cases 13 and 14) and 12 patients had advanced-stage lung adenocarcinoma (stage III: cases 4, 9 and 11; stage IV: all the rest cases). Therefore, a dual positivity of these 4 markers can be found in early stage lung adenocarcinoma cases. However, ALK rearrangement (7/8) and MET amplification (8/8) are mostly found in advanced stage lung adenocarcinoma cases (stage III+stage IV), whereas ROS1 and RET rearrangement are present in both early stage and advanced stage lung adenocarcinoma cases in this study (Table 2 ). Interestingly, 6 cases (cases 2, 6, 10, 12, 13 and 15) also had coexistent TP53 mutations; 5 cases (cases 1, 12-15) had EGFR mutations; 3 cases (cases 1, 8, 9) had KRAS mutations; and 2 cases (cases 6 and 14) had STK11 mutations detected by next-generation DNA sequencing. Although rare, all these cases demonstrate that co-alterations of tyrosine kinase function genes and tumor suppressor genes can be detected in lung adenocarcinoma cases. This phenomenon may be attributable to recurrence of disease even after an effective target-specific therapy.
All patients were treated according to stages with a combination of surgical resection, radiation therapy and therapeutic agents. Several patients received target-specific therapies, 5 with EGFR inhibitors (cases 1, 12-15), 3 with ALK inhibitors (cases 2, 5, and 7), and 3 with PD-1 inhibitors (cases 7, 8 and 12), but their clinical courses all show a temporarily partial response with local recurrence or new metastasis. One patient (case 12) is currently enrolled in a RET inhibitor trial, whereas no patients have been treated on a trial with ROS1 or MET inhibitor agents, although newly developed target-specific tyrosine kinase inhibitors may be an option during the course of their disease. 4, 8, 11 At last follow up, 3 patients (cases 1, 9 and 15) died and 12 patients remain alive with partial response to their treatments.
In summary, this is the first report showing concurrent rearrangement or amplification of ALK, RET, ROS1 or MET in lung cancer cases. Several of the cases in this study also had coexistent EGFR, KRAS and/or TP53 mutations. As recommended by the 2015 World Health Organization classification of lung tumors, comprehensive molecular profiling is very important for the workup of lung cancer, and the finding of multiple molecular alterations in lung cancer may have potential clinical implications for these patients.
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